인쇄하기
취소

LegoChem Bio’s Phase II clinical trial of ‘Super Antibody’ designated for accelerated approval by FDA

Published: 2018-02-14 10:58:24
Updated: 2018-02-14 10:58:24

LegoChem Biosciences(LegoChem Bio) officially announced that Delpazloid(LCB01-0371), a Phase II clinical trial pipeline, was designated as a medicine for the Fast Track process by the U.S. Food and Drug Administration(FDA).

Delpazolid, an antibody developed by LegoChem Bio on its own, has been on a Korean clinical trial with an oral indication for the treatment of multidrug-resistant tuberculo...

Fees

- Email service daily and homepage access.
  1. $300 per month.
  2. 5 Email holders per each company.
  3. Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.